UBS rated Neutral Osi Pharmaceuticals Inc. (NASDAQ: OSIP) on 03/02/2010. Previously UBS rated Buy Osi Pharmaceuticals Inc. (NASDAQ: OSIP) on 04/30/2009., when the stock price was $33.57. Since then, Osi Pharmaceuticals Inc. has gained 68.48% as of 03/02/2010's recent price of $56.56.
If you would have followed the previous UBS's recommendation on OSIP, you would have gained 68.48% of your investment in 306 days.

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

Marked as spam